Use of Hyperbaric Oxygen Therapy to Treat COVID-19 Patients With Respiratory Distress (NCT04800120) | Clinical Trial Compass
CompletedNot Applicable
Use of Hyperbaric Oxygen Therapy to Treat COVID-19 Patients With Respiratory Distress
United States6 participantsStarted 2021-02-15
Plain-language summary
Investigate whether hyperbaric oxygen therapy treatment can become a viable treatment option for COVID-19. If successful, providers will be able to provide future COVID-19 patients with mild-to-moderate respiratory distress hyperbaric oxygen therapy in order to help avoid mechanical ventilation
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Verified COVID-19 infection
* Patient w/02 dependence of less than or equal to 6 liter/min to maintain pulse ox greater than or equal to 92% or arterial gas w/PA02 greater than 60mm HG
Exclusion Criteria:
* Not diagnosed w/COVID-19 infection
* Pregnancy
* DNR or other restrictions in escalation of level of care
* Contraindication for HBO
* Blood pressure parameters which are deemed unstable by clinical team
* Patients who require continuous ECG and/or continuous blood pressure monitoring, and with arterial lines
* Patients requiring rewarming
* Patients requiring any kind of invasive catheter/pressure monitoring
* Patients requiring continuous support of intravenous medication
* Minor subject (less than 18 years old)
* Refusal to participate
* Signs of respiratory decompensation requiring intubation and mechanical ventilation
* 02 dependence greater than or equal to 6L/minute to obtain Sa02 greater than or equal to 92% or ABG w/Pa02 \>60mmHg
What they're measuring
1
Normalization of oxygen
Timeframe: through study completion, an average of 1 year
Trial details
NCT IDNCT04800120
SponsorSteward St. Elizabeth's Medical Center of Boston, Inc.